Patent application number | Description | Published |
20100197621 | METHODS OF REDUCING THE PROLIFERATION AND VIABILITY OF MICROBIAL AGENTS - The invention relates to formulations of an antimicrobial agent, a lipid, and optionally a surfactant, and uses thereof for reducing the proliferation and viability of microbial agents. | 08-05-2010 |
20100249027 | CRF CONJUGATES WITH EXTENDED HALF-LIVES - The present invention relates to conjugates of CRF that have been modified to include a moiety that protects CRF from degradation and prolongs the half-life of CRF. The CRF conjugates of the invention have an increased half-life which results in a dose-sparing effect and less frequent administration | 09-30-2010 |
20110183906 | FACTOR IX CONJUGATES WITH EXTENDED HALF-LIVES - The present invention relates to conjugates of Factor IX that have been modified to include a biocompatible polymer moiety. The Factor IX conjugates are substantially free of contamination by Factor IXa. The Factor IX conjugates have improved pharmacokinetic properties, such as increased half-life, which results in dose sparing and less frequent administration. | 07-28-2011 |
20120232034 | VESICULAR FORMULATIONS - Disclosed herein are vesicular formulations that include one or more phospholipids and one or more surfactants and in certain embodiments the use of such formulations for the delivery of fatty acids for the treatment of disorders such as, fatty acid metabolic disorders, including essential fatty acid deficiency; pain or inflammation or osteoarthritis, more specifically for the treatment of deep tissue pain; asthma, bronchospasm, atherothrombatic cardiovascular disorders, avenous thrombatic disorders, inflammatory dermatoses disorders (e.g., atopic eczema, dishydrotic hand eczema, plaque type psoriasis, seborrheic eczema, and acne vulgaris), and dysmenorrhea. | 09-13-2012 |
20120245107 | METHODS OF REDUCING THE PROLIFERATION AND VIABLILITY OF MICROBIAL AGENTS - The invention relates to formulations of an antimicrobial agent, a lipid, and optionally a surfactant, and uses thereof for reducing the proliferation and viability of microbial agents. | 09-27-2012 |
20130129698 | CONJUGATED BLOOD COAGULATION FACTOR VIIA - The present invention provides a biocompatible polymer conjugated to FVIIa via one or more cysteine residues, suitably via a linker across a reduced disulphide bond in FVIIa, and pharmaceutical compositions comprising such conjugated forms of FVIIa. | 05-23-2013 |
20130150302 | CONJUGATED BLOOD COAGULATION FACTOR VIII - The present invention provides a biocompatible polymer conjugated to FVIII via one or more cysteine residues, suitably via a linker across a reduced disulphide bond in FVIII, and pharmaceutical compositions comprising such conjugated forms of FVIII. | 06-13-2013 |
20140100191 | Vesicular Formulations - Disclosed herein are vesicular formulations that include one or more phospholipids and one or more surfactants and in certain embodiments the use of such formulations for the delivery of fatty acids for the treatment of disorders such as, fatty acid metabolic disorders, including essential fatty acid deficiency; pain or inflammation or osteoarthritis, more specifically for the treatment of deep tissue pain; asthma, bronchospasm, atherothrombatic cardiovascular disorders, avenous thrombatic disorders, inflammatory dermatoses disorders (e.g., atopic eczema, dishydrotic hand eczema, plaque type psoriasis, seborrheic eczema, and acne vulgaris), and dysmenorrhea. | 04-10-2014 |